PE20020453A1 - Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos - Google Patents
Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidosInfo
- Publication number
- PE20020453A1 PE20020453A1 PE2001000955A PE2001000955A PE20020453A1 PE 20020453 A1 PE20020453 A1 PE 20020453A1 PE 2001000955 A PE2001000955 A PE 2001000955A PE 2001000955 A PE2001000955 A PE 2001000955A PE 20020453 A1 PE20020453 A1 PE 20020453A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- inhibitors
- phenoxyphenoxy
- alkenyl
- propyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A ACIDOS BENZOPIRANCARBOXILICOS DE FORMULA I DONDE R1 ES H, OH, ALQUILO C1-C7, ALQUENILO C2-C7, ALQUINILO C2-C7, O-ALQUIL C1-C3, CR11R12; R11 Y R12 SON H, HALOGENO, ALQUILO C1-C5, ALQUENILO C2-C5, ALQUINILO C2-C5; Z ES CH2, C=O; X E Y SON O, S, SO2, SO, CH2; n ES 1-6; R4 ES OAr; R2, R3, R5, R6, R7, R8, R9, 10 SON H, HALOGENO, ALQUILO C1-C7, ALQUENILO C2-C7, ALQUINILO C2-C7, OH, O-ALQUIL C1-C5; SON COMPUESTOS PREFERIDOS 7-(3-(2-PROPIL-4-FENOXIFENOXI)PROPOXI)-CROMANO-2-ACIDO CARBOXILICO; 7-(3-(2-PROPIL-4-FENOXIFENOXI)PROPOXI)-2-PROPILCROMANO-2-ACIDO CARBOXILICO; 7-(4-(2-PROPIL-4-FENOXIFENOXI)BUTOXI)-CROMANO-2-ACIDO CARBOXILICO; ENTRE OTROS; TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS a)UN INHIBIDOR DE REDUCTASA HMGCoA: i)AGONISTAS PPARg ( GLITAZONAS; BIGUANIDAS); ii)INHIBIDORES DE TIROSIN FOSFATASA 1B; iv)INHIBIDORES DE PEPTIDOFOSFATASA COMO LOVASTATINA, SIMVASTATINA, PRAVASTATINA, FLUVASTATINA; b)INSULINA, c)SULFONILUREAS (TOLBUTAMINA, GLIPIZIDA, d)INHIBIDORES DE a-GLUCOSIDASA (ACARBOSA), e)AGENTES REDUCTORES DE COLESTEROL (EZETIMIBE), f)COMPUESTOS ANORECTICOS COMO FENFLURAMINA, FENTERMINA; ENTRE OTROS; g)AGENTES ANTIINFLAMATORIOS. LOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR ACTIVADO POR LOS PROLIFERADORES DE PEROXISOMA PPARg Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DIABETES, HIPERGLUCEMIA, HIPERLIPIDEMIA, HDL BAJA, OBESIDAD, HIPERCOLESTEROLEMIA, HIPERTRIGLICERIDEMIA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23570800P | 2000-09-27 | 2000-09-27 | |
US24469700P | 2000-10-31 | 2000-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020453A1 true PE20020453A1 (es) | 2002-06-06 |
Family
ID=26929158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000955A PE20020453A1 (es) | 2000-09-27 | 2001-09-21 | Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos |
Country Status (7)
Country | Link |
---|---|
US (1) | US6645997B2 (es) |
EP (1) | EP1324995A2 (es) |
JP (1) | JP2004513090A (es) |
AU (2) | AU9287401A (es) |
CA (1) | CA2423141A1 (es) |
PE (1) | PE20020453A1 (es) |
WO (1) | WO2002026729A2 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2347095A1 (en) * | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Nitrogen-containing condensed heterocyclic derivatives, their production and agent |
GEP20043286B (en) * | 2000-02-02 | 2004-07-26 | Warner Lambert Co | Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders |
US20020183305A1 (en) * | 2001-01-26 | 2002-12-05 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
ES2290562T3 (es) * | 2001-01-26 | 2008-02-16 | Schering Corporation | Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares. |
DE60221798T2 (de) * | 2001-01-26 | 2008-06-05 | Schering Corp. | Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen |
WO2002058734A2 (en) * | 2001-01-26 | 2002-08-01 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
CZ20032031A3 (cs) * | 2001-01-26 | 2003-12-17 | Schering Corporation | Farmaceutický prostředek |
WO2003088962A1 (en) * | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
DE60332738D1 (de) * | 2002-07-30 | 2010-07-08 | Merck Sharp & Dohme | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen |
WO2004010948A2 (en) | 2002-07-30 | 2004-02-05 | Karykion Inc. | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
KR100492252B1 (ko) * | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
US7192970B2 (en) | 2002-11-26 | 2007-03-20 | Chipscreen Biosciences, Ltd. | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity |
US20040242568A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
EP1630152A4 (en) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
ATE457166T1 (de) * | 2003-07-24 | 2010-02-15 | Wockhardt Ltd | Orale zusammensetzungen zur behandlung von diabetes |
US7790736B2 (en) * | 2003-08-13 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ITTO20030140U1 (it) * | 2003-09-16 | 2005-03-17 | Interfila Srl | Matita cosmetica |
CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
US20080058292A1 (en) * | 2003-10-29 | 2008-03-06 | Raif Tawakol | Method for increasing HDL and HDL-2b levels |
WO2005041878A2 (en) * | 2003-10-29 | 2005-05-12 | Tawakol Raif M D | Compositions and methods for increasing hdl and hdl-2b levels |
CN102134229B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US7635779B2 (en) * | 2004-10-15 | 2009-12-22 | Council Of Scientific & Industrial Research | Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents |
WO2006055187A1 (en) * | 2004-10-29 | 2006-05-26 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of ppar |
CN101421258B (zh) * | 2004-10-29 | 2013-08-21 | 凯利普西斯公司 | 作为ppar调节剂的磺酰基取代的双环化合物 |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
PL1942898T5 (pl) | 2005-09-14 | 2014-10-31 | Takeda Pharmaceuticals Co | Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy |
US20070060529A1 (en) * | 2005-09-14 | 2007-03-15 | Christopher Ronald J | Administration of dipeptidyl peptidase inhibitors |
KR101352588B1 (ko) * | 2005-09-14 | 2014-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
US20070161006A1 (en) * | 2006-01-10 | 2007-07-12 | Vita Genomics, Inc. | Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma |
JP2010502719A (ja) | 2006-09-08 | 2010-01-28 | ロード アイランド ホスピタル | アルコール誘発性脳疾患の治療、予防および回復 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
GEP20125701B (en) * | 2006-09-13 | 2012-12-10 | Takeda Pharmaceuticals Co | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
KR101934197B1 (ko) * | 2017-06-12 | 2018-12-31 | 아주대학교산학협력단 | PPARα/γ 이중 작용 활성을 갖는 신규 화합물 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 조성물 |
ES2718000B2 (es) * | 2017-12-26 | 2019-12-20 | Univ Valencia | Benzopiranos prenilados agonistas de ppar |
CN115093389A (zh) * | 2022-05-31 | 2022-09-23 | 广州医科大学 | 6-酰胺色满-3-甲酰胺衍生物及其制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474788A (en) | 1981-11-12 | 1984-10-02 | Fisons Plc | Anti-SRSA quinoline carboxylic acid derivatives |
US4680404A (en) * | 1983-01-13 | 1987-07-14 | Pfizer Inc. | Benzopyrans |
ZA844519B (en) | 1983-06-24 | 1985-02-27 | Hoffmann La Roche | Dihydrobenzopyran derivatives |
US4778903A (en) * | 1983-12-12 | 1988-10-18 | G. D. Searle & Co. | Substituted dihydrobenzopyrans |
AU548450B2 (en) | 1983-08-08 | 1985-12-12 | G.D. Searle & Co. | Substituted dihydrobenzopyrans |
US4565882A (en) | 1984-01-06 | 1986-01-21 | G. D. Searle & Co. | Substituted dihydrobenzopyran-2-carboxylates |
US4885309A (en) | 1986-08-01 | 1989-12-05 | Hoffmann-La Roche Inc. | Therapeutic treatment of leukotriene-mediated dermal inflammation by topical administration of 3,4-dihydro-2H-1-benzopyran derivatives |
US5112856A (en) | 1986-08-15 | 1992-05-12 | Hoffmann-La Roche Inc. | Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives |
US4889871A (en) * | 1987-05-29 | 1989-12-26 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives |
EP0336068A1 (en) | 1988-02-11 | 1989-10-11 | F. Hoffmann-La Roche Ag | Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives |
US5003090A (en) * | 1988-08-23 | 1991-03-26 | Hoffmann-La Roche Inc. | Process for the preparation of benzopyrans |
US5073562A (en) | 1990-05-10 | 1991-12-17 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof |
US5124350A (en) | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
US5352690A (en) | 1992-07-01 | 1994-10-04 | Eli Lilly And Company | 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists |
US5324743A (en) | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
US5478857A (en) | 1993-12-23 | 1995-12-26 | Eli Lilly And Company | Use of PLA2 inhibitors as treatment for alzheimer's disease |
US6235785B1 (en) | 1994-08-31 | 2001-05-22 | Eli Lilly And Company | Methods for identifying and treating resistant tumors |
EP0743064A1 (en) | 1995-05-17 | 1996-11-20 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease |
EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
DE69931504D1 (de) | 1998-08-28 | 2006-06-29 | Intarcia Therapeutics Inc | Zusammensetzungen zur linderung der nebeneffekte des interleukin-2 |
AUPP609198A0 (en) * | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
-
2001
- 2001-09-21 PE PE2001000955A patent/PE20020453A1/es not_active Application Discontinuation
- 2001-09-21 JP JP2002531113A patent/JP2004513090A/ja not_active Withdrawn
- 2001-09-21 EP EP01973277A patent/EP1324995A2/en not_active Withdrawn
- 2001-09-21 AU AU9287401A patent/AU9287401A/xx active Pending
- 2001-09-21 CA CA002423141A patent/CA2423141A1/en not_active Abandoned
- 2001-09-21 WO PCT/US2001/029456 patent/WO2002026729A2/en active Application Filing
- 2001-09-21 AU AU2001292874A patent/AU2001292874B2/en not_active Ceased
- 2001-09-24 US US09/961,841 patent/US6645997B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002026729A3 (en) | 2002-08-15 |
US6645997B2 (en) | 2003-11-11 |
AU2001292874B2 (en) | 2006-06-15 |
JP2004513090A (ja) | 2004-04-30 |
CA2423141A1 (en) | 2002-04-04 |
EP1324995A2 (en) | 2003-07-09 |
US20020082292A1 (en) | 2002-06-27 |
AU9287401A (en) | 2002-04-08 |
WO2002026729A2 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020453A1 (es) | Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos | |
PE20020354A1 (es) | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) | |
PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
PE20011184A1 (es) | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa | |
AR023703A1 (es) | N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa | |
PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
PE20020540A1 (es) | Derivados del acido benzo pirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos | |
AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
PE20020858A1 (es) | Indanil aminas aciladas | |
PE20081782A1 (es) | Agonistas de adrenoreceptores alfa2c | |
PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
AR016523A1 (es) | Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento | |
PE20011067A1 (es) | Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas | |
AR031305A1 (es) | Agonistas del receptor alfa activado del proliferador de peroxisomas | |
BRPI0817096B8 (pt) | análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
AR020661A1 (es) | Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento | |
PE20061451A1 (es) | Compuestos derivados de diarilsulfona sulfonamidas | |
PE107999A1 (es) | Derivados 3-amidinoanilina, inhibidores del factor x de coagulacion de la sangre activado e intermediarios de los mismos | |
TR200000671T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. | |
AR058760A1 (es) | Derivados de aril -isoxasol -4-il- imidazol | |
AR067954A1 (es) | Compuestos de carbazol | |
ES2159347T3 (es) | Naftil-acetamidas como inhibidores de spla2. | |
PE20050160A1 (es) | 3-aminopirrolidinas como inhibidores de la captacion de monoaminas | |
PE20050293A1 (es) | Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos | |
ATE243215T1 (de) | Neue 2-decarboxy-2-phosphinico prostaglandin f analoge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |